कौन ज़िम्मेदार? KaunZimmedar

No PLI Scheme applicant from Akola district in Maharashtra

The question asked the Ministry of Chemicals and Fertilizers to provide details on the implementation of Production Linked Incentive (PLI) schemes, bulk drug parks, and financial assistance for pharmaceutical manufacturing in Maharashtra, specifically in Akola district and the Vidarbha region.

Asked by: Shri Anup Sanjay Dhotre and Prof. Varsha Eknath Gaikwad; Answered by: Ministry of Chemicals and Fertilizers (Minister of State Smt. Anupriya Patel).

  • 48 projects approved under PLI Scheme for Bulk Drugs with cumulative investment of ₹5,070.45 crore as of March 2026.
  • 55 companies selected under PLI Scheme for Pharmaceuticals with cumulative investment of ₹45,774 crore and 1,16,884 jobs generated as of March 2026.
  • Three Bulk Drug Parks approved in Andhra Pradesh, Gujarat, and Himachal Pradesh with a total project cost of over ₹6,300 crore.
  • Three Medical Device Parks approved in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu.
  • Maharashtra has 5 approved projects under PLI Bulk Drugs (investment ₹138 crore) and 14 approved applicants under PLI Pharmaceuticals (investment ₹9,874.08 crore).
  • No approved applicant under the PLI Scheme for Pharmaceuticals belongs to Akola district, Maharashtra.
  • There is no provision for state-wise allocation of budget under the PLI schemes; incentives are disbursed based on meeting investment and sales targets.

Written from the document by AI, and checked against it. The original below is authoritative.

The original document

Parliamentary Q&A 07.08.2026
Tap “Open the PDF” above to view this document.
Document details
Official titlePromotion of Pharmaceutical Manufacturing in Maharashtra
Source bodyParliament of India — Questions & Answers (Lok Sabha, starred)
Reference numberLS Q282 (Session 8)
Statusclosed (question)
Year07.0
Closing date
Documents1

Discussion (0)

Citizens discussing these documents. A discussion space — nothing here is verified fact or an official finding. Reading is free; sign in to take part.

Open discussion (0) →